The Problem of Accessibility of Orphan Medicinal Products in the Light of the Right to Health Care
##plugins.themes.bootstrap3.article.main##
Abstract
Currently in the European Union (EU) approximately 30 million people suffer from rare diseases. A European policy on rare disorders was put into action with the Regulation (EC) 141/2000 adopted on December 16, 1999, setting out a Community procedure for the designation of medicinal products and providing incentives for research, development and marketing of orphan medicinal products in the EU. The legislation on orphan medicinal products is a part of a broader Community policy to identify rare diseases as a priority area for action in the field of public health, which constitutes the area of common competence of EU and Member States.
##plugins.themes.bootstrap3.article.details##
Section
Articles
Authors contributing to Jurisprudence agree to publish their articles under a Creative Commons Attribution-NoDerivatives 4.0 International Public (CC BY-NC-ND) License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this licence are made clear.
Authors retain copyright of their work, with first publication rights granted to the Association for Learning Technology.
Please see Copyright and Licence Agreement for further details.
Authors retain copyright of their work, with first publication rights granted to the Association for Learning Technology.
Please see Copyright and Licence Agreement for further details.
